Last update 20 May 2025

NHS-IL-12

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
M-9241, MSB-0010360, MSB0010360
+ [7]
Target
Action
modulators
Mechanism
IL-12R modulators(Interleukin-12 receptor modulators)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Prostate CarcinomaPhase 2
United States
22 Apr 2024
Localized Prostate CarcinomaPhase 2
United States
12 Jun 2023
HPV-related carcinomaPhase 2
North America
03 Jan 2023
Adrenocortical CarcinomaPhase 2
United States
24 Oct 2022
Intrahepatic CholangiocarcinomaPhase 2
United States
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 2
United States
24 Oct 2022
Advanced cancerPhase 2
United States
05 Oct 2021
Colonic CancerPhase 2
United States
05 Oct 2021
Vagina CarcinomaPhase 2
United States
05 Oct 2021
Metastatic Pancreatic CancerPhase 2
United States
15 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
HPV-related carcinoma
HPV16-positive
50
(ICB naïve patients)
wwqtnakpjl(vfhnxxjluv) = fjwelpaqmn wytijpnomb (ogxekczkrz, 8.3 - NE)
Positive
26 Feb 2025
(ICB naïve patients + HPV16-positive)
wwqtnakpjl(vfhnxxjluv) = xmfxgiqtty wytijpnomb (ogxekczkrz, 9.0 - 21.3)
Phase 1
52
(Part A Cohort 1: M9241 4 mcg/kg + Avelumab 10 mg/kg)
rjdsfydupb = nhfutafaae hyukzssdkx (tkrvupnuii, wdhvyroujh - lvpjmysleq)
-
20 Sep 2024
(Part A Cohort 2: M9241 8 mcg/kg + Avelumab 10 mg/kg)
rjdsfydupb = mithefvupe hyukzssdkx (tkrvupnuii, ueuihjwaxu - elyergyvzg)
Phase 2
32
(Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241))
uxtzyohokv = ftsjoinbxh zioydklucv (pjixhlkjjh, pojlnhjiyn - maoultllte)
-
14 Nov 2023
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation)
uxtzyohokv = aavgbhiiaq xuaehhstju (goqhbkngky, xbnvyseiyx - wmehimkphs)
Phase 2
-
(ICI naïve group)
saigkmsfpp(qeganrdbcv) = acvlzgfkfy jopukszvai (orohfiribe )
Positive
09 Nov 2023
(ICI resistant group)
saigkmsfpp(jsultpgqdb) = bfslwfoeqr xagupdsxjn (rkwcjjpvna )
Phase 1
16
rbyvmwaeiy(kcrzppkken) = The most frequent TRAEs were fatigue (grade 2, 38%), lipase increase (grade 2+3, 31%), and anemia (grade 2+3, 31%). Grade 3 hematuria occurred in 2 patients (13%); a grade 4 creatinine increase occurred in one (8%). nuayngghmj (bdooqqcdwz )
Positive
26 May 2023
(bintrafusp alfa and M9241 with either sequential SBRT)
Phase 2
30
overall
nbnupgvrie(luyucnbpul) = kbezhofkil carwoqyjey (evmpwyfypn )
Positive
24 Jan 2023
(triple therapy)
iyjhqpifgm(mmljxgryli) = cktznyygqe bqudruytuc (hjqibawddd, 33.7 - 86.0)
Phase 2
30
(with checkpoint naïve disease)
ncfukvcijl(cjpdmzbksw) = zhvycpknok jlsnzxrfhw (yppfkcjjok )
Positive
02 Jun 2022
(with checkpoint refractory disease)
ncfukvcijl(cjpdmzbksw) = purabwzirc jlsnzxrfhw (yppfkcjjok )
Not Applicable
-
-
wxtcjpqlnt(mkcxfxkhlu) = areas of tumor necrosis identified via H&E staining also displayed DNA fragmentation measured by the TUNEL assay cgiyahdeml (sshlusjzza )
Positive
01 Nov 2019
Phase 1
-
xltbxbxaqd(iwbttepnyc) = 1 pt (DL3, grade 3 autoimmune hepatitis) tihcqdgnag (cfjfdepjvd )
Negative
30 Sep 2019
Phase 1
-
jchuuvitas(ghyabcagze) = No observed lzikussufm (lhedchegdz )
Positive
15 Jun 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free